Publications by authors named "Catherine Geh"

Claim this Profile
H
Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B.
Timo Vögtle, Sumana Sharma, Jun Mori, Zoltan Nagy, Daniela Semeniak, Catherine Geh

Elife· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Alex Pearson, Elizabeth Smyth, Irina S Babina, Maria Teresa Herrera-Abreu, Noelia Tarazona, Catherine Geh

Cancer Discov· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
Claire Rooney, Catherine Geh, Victoria Williams, Johannes M Heuckmann, Roopika Menon

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples.
Margaret H Veldman-Jones, Roz Brant, Claire Rooney, Catherine Geh, Hollie Emery

Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Kate F Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Catherine Geh

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Kate F Byth, Catherine Geh

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Paula Daunt, Catherine Geh

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.
Kate F Byth, Catherine Geh, Cheryl L Forder, Sandra E Oakes, Andrew P Thomas

Mol Cancer Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis